{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-014380","form_type":"8-K","ticker":"IMDX","cik":"0001642380","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2024-04-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.390764+00:00","generated_at":"2026-06-03T23:24:44.482698+00:00","sec_items":["1.01","2.02","7.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Oncocyte raises $15.8M in private placement; FY2023 revenue $1.5M, ops loss $25.1M","bullets":["Private placement of 5.1M shares + pre-funded warrants for 342k shares at $2.92/share; gross proceeds ~$15.8M.","Expected close April 15, 2024; $5M of proceeds to redeem Series A Preferred Stock; remainder for working capital.","FY2023 revenue $1.5M (+57%); operating loss $25.1M (+40%); cash burn Q4 2023 $4.4M, Q1 2024 est. $3.8M.","Bio-Rad partnership for transplant monitoring IP; GraftAssure product launch on track for Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-014380","json":"https://secwatch.observer/filing/0001493152-24-014380.json","markdown":"https://secwatch.observer/filing/0001493152-24-014380.md","text":"https://secwatch.observer/filing/0001493152-24-014380.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642380/000149315224014380/0001493152-24-014380-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642380/000149315224014380/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T23:24:44.482698+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ba7b25bad9b12b186ec0f1b1383447639461d67a","claim":"Insight Molecular Diagnostics Inc. reported year ended December 31, 2023 results: revenue $1.5 million.","evidence_excerpt":"commercial and regulatory milestones.” 2023 Fourth Quarter and Full-Year Financial Results Net revenue for the three months and year ended December 31, 2023, was $314,000 and $1.5 million, respectively, an increase of 15% compared to the fourth quarter 2022 and 57% compared to the full year 2022, due to increased revenue from Pharma Services. Cost of revenues for","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315224014380/0001493152-24-014380-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2023"},{"label":"Revenue","value":"$1.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"d7d99eb62a96aa377316820af7651b7bc2859e7d","claim":"Insight Molecular Diagnostics Inc. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $15.8 million (effective 2024-04-11).","evidence_excerpt":"On April 11, 2024, Oncocyte Corporation (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors (collectively, the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement”) of an aggregate of 5,077,387 shares (the “Common Shares”) of common stock of the Company, no par value per share (the “Common Stock”), and pre-funded warrants (“Pre-Funded Warrants”) to purchase up to 342,888 shares of Common Stock, with an exercise price of $0.0001 per share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315224014380/0001493152-24-014380-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Value","value":"approximately $15.8 million"},{"label":"Effective","value":"2024-04-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}